

developed metastatic disease. Median intervals between surgery and local or metastatic relapse were respectively 14 and 13 months. Overall actuarial survival and disease-free survival at 2 years are respectively 77 and 47%. Grade, tumor size, tumor depth, bony or neurovascular involvement as well as quality of surgery show significant effects on DFS. Considering prognosis, hyperfractionated radiotherapy did not seem to be superior to standard techniques.

Long term side-effects, although usually mild, occurred in 35% of the patients. Dose of therapy, but not size of treatment fields, positively influenced them.

846 ORAL
NEOADJUVANT SYSTEMIC CHEMOTHERAPY COMBINED WITH REGIONAL HYPERTHERMIA IN ADVANCED OR RECURRENT SOFT TISSUE SARCOMA: RESULTS OF THE RHT-91 STUDY

R.D. Issels, R. Pihusch, Ch. Salat, S. Rahman, K.-W. Jauch, F.W. Hagena, W. Wilmanns

GSF-Institut für Klinische Hämatologie und Medizinische Klinik III, Klinikum Großhadern, D-81377 Munich, Germany

From Nov. 1990 to Oct. 1994 a total of 97 (72% pretreated) adults with locally-advanced, nonmetastatic soft tissue sarcomas were entered in a protocol (RHT-91) involving regional hyperthermia (RHT) combined with systemic preoperative chemotherapy followed by surgery. Primary tumor grading (84 patients had grade II or III), tumor size (>8 cm) and/or extracompartmental tumor extension (46 patients), or local recurrences (51 patients) were defined as high-risk factors. RHT was produced by an electromagnetic regional heating device (BSD-2000 system). For systemic chemotherapy the 97 patients received etoposide/ifosfamide/doxorubicin (EIA) with RHT being given on day 1 and 4 in repeated cycles (EIA/RHT) every 3 weeks. By the cutoff date for this analysis (Oct. 1994), 70 patients had undergone surgery after receiving EIA chemotherapy combined with RHT; 60 tumors except 10 could be resected without amputation. In 27 patients no further surgical procedure was performed. In 92 evaluable patients, the clinical response rate is 34% (1 CR = complete, 15 PR = partial, 17 MR = minor). 41 patients showed stable disease (NC) and 18 patients showed tumor progression (PD). Pathologic response to preoperative thermochemotherapy was evaluable in 70 patients with 30 responders (=43%) having either >50% histologic necrosis (FHR) within the resected tumors (20 patients) or pathological complete response (pCR) at the time of surgery (10 patients). All patients received—whenever possible—adjuvant chemotherapy and postoperative radiation. At the cutoff date, best response was obtained by the strategy of the RHT-91 study in 40 patients (=41%) showing no evidence of disease (NED) (median observation time = 18 months). An updated report will be given in regard to overall survival for non chemo-pretreated ($n = 73$) and chemo-pretreated ($n = 24$) patients. The protocol of a randomized multicenter trial (RHT-95) in patients with primary or recurrent high-risk soft tissue sarcomas will be presented to further test the potential of preoperative thermochemotherapy compared to neoadjuvant chemotherapy alone in regard to local control and survival.

Supported by grant M19/88/Wi9 from the Deutsche Krebshilfe, Bonn.

847 ORAL
CONSERVATIVE LOCAL TREATMENT BY MULTIMODALITY THERAPY IN 361 ADULTS' SOFT TISSUE SARCOMA (STS)

E. Stöckle, P. Lagarde, L. Thomas, M. Kind, J.M. Coindre, B.N. Bui

Institut Bergonié, 180, rue de Saint-Genès, 33076 Bordeaux Cedex, France

Methods: From 1975 to 1992, 361 patients (pts) had their initial treatment at Institut Bergonié for non metastatic STS. There were 210 males and 151 females at a mean age of 50 years (16–87 years). 59% of the tumours were localized in the extremities. All pathological slides have been centrally reviewed. Grading according to the FNCLCC system was: G1 (18%), G2 (44%), G3 (38%). The local treatment combined surgery and radiotherapy in 83% of the cases. Surgery was conservative when possible. Marginal surgery was performed in 45% of the cases, wide excision in 48%. Compartmental radiotherapy was performed at a dose of 50 Gy, associated with a local boost (external beam, intraoperative or brachytherapy) when surgery was marginal. Chemotherapy was given in 126 pts (35%), in 60 of whom preoperatively.

Results: Amputation was necessary in only 7 pts (2%). Complete remission was obtained in 97.5%. Severe local complications occurred in

26 patients (7.2%). With a median follow-up of 6 years (1–20 years) local recurrence occurred in 21.4% of the cases, and metastasis in 28.7%. Actuarial 5-year overall and disease free survival are 66% and 59%. The function of the treated members was good in 92% of the pts. In univariate analysis, no difference was seen in local recurrence after marginal vs large excision when radiotherapy was done.

Conclusion: These treatment results compare favourably to those found in the literature. Satisfying functional outcome without amputation can be obtained by a multidisciplinary treatment approach.

848 ORAL
DOCETAXEL (TAXOTERE) AS FIRST LINE THERAPY FOR METASTATIC OR RECURRENT SOFT TISSUE SARCOMA (STS): A PHASE II TRIAL

M.E. Blackstein, E.A. Eisenhauer, V. Bramwell, K. Belanger, S. Verma, S. Beare

National Cancer Institute of Canada, Clinical Trials Group 1222-600 University Ave., Toronto, Canada M5G 1X5

The clinical trials group of the National Cancer Institute of Canada is performing a multi-institutional phase II study of docetaxel in patients (pt) with measurable metastatic or recurrent sts with no prior systemic therapy. The starting dose is 100 mg/m² q 3 weeks with dose reduction for severe toxicities. Premedication includes 20 mg oral (po) dexamethasone (D) at 12 and 6 hours (hr) before, 50 mg diphenhydramine and 50 mg ranitidine both iv 1/2 hr before a 1 hr infusion docetaxel followed by 8 mg D po every 12 hr for 6 doses.

To date 22 pt have been entered, 1 is ineligible, 6 are too early for evaluation, 13 are evaluable for response and 15 for toxicity. Two partial responses and 6 stable disease have been reported. There have been 2 deaths on study unrelated to drug toxicity. The most common side effects have been: grade III–IV neutropenia (25/32 courses) with a median nadir of $0.4 \times 10^9/l$ granulocytes; five cases of febrile neutropenia and two with severe infection. There have been five hypersensitivity reactions only one severe. Mild-moderate lethargy (10 pt) and edema (5 pt) have also been seen. The median delivered dose intensity is 33.14 mg/m².

Because two responses have been documented the trial will continue until 30 evaluable pt have been entered. At the current rate of accrual it is expected that the final response rates and toxicities will be available by the time of presentation.

849 ORAL
PRELIMINARY REPORT OF A RANDOMIZED PHASE II STUDY COMPARING TWO DIFFERENT IFOSFAMIDE (IF) REGIMENS IN ADVANCED SOFT TISSUE SARCOMA PATIENTS (PTS) FAILING FIRST-LINE ANTHRACYCLINES

A.T. van Oosterom, H.T. Mouridsen, P. Dombernowski, O.S. Nielsen, C. van Pottelsberghe, M. van Glabbeke, T. Tursz

EORTC Soft Tissue and Bone Sarcoma Group

Soft tissue sarcomas (STS) constitute 1% of all malignant tumors. Despite optimal local treatment 50% of pts will relapse. First-line chemotherapy is Ddoxorubicin 75 mg/m². The STS group performed a large ph 3 study comparing different anthracyclines. Patients failing at that study were eligible and randomized to receive (a) If 5 g/m² over 24 hrs or (b) If 3 g/m² in 4 hrs d 1–3 q 3 wks, both with adequate Mesna protection. A total of 86 pts of whom 78 evaluable and 66 off study were entered. Age 50 yrs (22–75), M = F, PS: 27:0, 51:1. Leyomyosarcoma 30/78. **Results:** 34 PD, 1 CR on A, 1 CR and 2 PR on B, RR 3 resp. 8%. No change (NC) resp. 9 and 17 pts. So progression arrest (Resp + NC) 35% with (a) and 53% with (b). **Toxicity:** both gr 3 + 4 leucopenia and thrombocytopenia were more pronounced with B: 33 vs 68% and 3 vs 15% and nadirs of Wbc 3.1 vs 1.35, Pt 203 vs 169.10⁹/l. Non hem. tox. did not differ substantially.

Conclusion: Higher IF results in more progression arrest and more manageable toxicity, but the overall response rate is disappointing.

850 ORAL
POST-RADIATION SARCOMAS: PRESENTATION OF A SERIES OF 116 CASES

J.L. Lagrange, P. Richaud, C. Marchal, M. Resbeut, P. Rambert, J. Torochaux, S.H. Seng, B. De La Fontan, M. Reme-Saunon

Radiation Therapy Group of the FNCLCC, Centre A.Lacassagne, 36, Voie Romaine, 06050 Nice Cx, France

Post-radiation sarcomas are a rare and late complication of radiation treatment. The majority of them develops after 10 years.